COMMUNIQUÉS West-GlobeNewswire

LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
06/07/2026
VIZZ is now available for those who qualify through a convenient telehealth platform in addition to existing access through eye care professionals Telehealth offers patients the convenience of an integrated online [...]
PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset
06/07/2026
TORONTO, July 06, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) , a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives [...]
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
06/07/2026
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative [...]
GuideAI Health Appoints Renowned Interventional Radiologist Dr. James Benenati to Advisory Board Following FDA 510(k) Clearance of VAOT
06/07/2026
Leading Vascular Specialist and Penumbra Chief Medical Officer Joins GuideAI to Help Advance Its Recently FDA-Cleared VAOT Triage Software BOSTON, July 06, 2026 (GLOBE NEWSWIRE) -- GuideAI Health Corp. (Cboe CA: GDAI [...]
Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on July 6, 2026
06/07/2026
MINNEAPOLIS, July 06, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the second quarter 2026 after the close of trading on Monday, August 3. Inspire’s [...]
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
06/07/2026
NORWOOD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing promising new therapies in oncology and [...]
Canada Diagnostic Centres, a Novacap Portfolio Company, Announces Acquisition of Shift Imaging
06/07/2026
CALGARY, Alberta, July 06, 2026 (GLOBE NEWSWIRE) -- Canada Diagnostic Centres ("CDC"), a Novacap portfolio company and a leading Canadian community-based diagnostic imaging provider, today announced the acquisition of [...]
ThreeSixty Journalism Kicks Off Multimedia Storytelling Institute Summer Program for Local High School Students
06/07/2026
Summer Program Gives High School Students Hands-On Reporting Experience Exploring Mental Health and Wellness Across Minnesota ST. PAUL, Minn., July 06, 2026 (GLOBE NEWSWIRE) -- This July, ThreeSixty Journalism will kick [...]
Catheter Precision, Inc. Announces Issuance of Two Key Patents
06/07/2026
New Intellectual Property Covers VIVO Technology and Cardionomix Heart Failure Technology FORT MILL, SC, July 06, 2026 (GLOBE NEWSWIRE) -- Catheter Precision Inc., (VTAK: NYSE/American), a US based medical device [...]
La recommandation du CMUH fait passer le TECVAYLI®▼ (teclistamab) de Johnson & Johnson, associé au daratumumab, au rang de traitement conventionnel potentiel pour le myélome multiple récidivant ou réfractaire
06/07/2026
Recommandation étayée par des données inédites issues d’une étude de Phase 3, démontrant que TECVAYLI ® , en association avec le daratumumab, a permis d’obtenir des améliorations statistiquement significatives en termes [...]
TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia
06/07/2026
Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60 patients with treatment-resistant schizophrenia based on emerging evidence linking immune dysfunction to disease in a subset of [...]
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026
06/07/2026
Latest findings on neflamapimod to be featured in presentations demonstrating its impact on dementia with Lewy bodies (DLB) disease progression, biomarkers of neurodegeneration, and basal forebrain atrophy, as well as [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
06/07/2026
COPENHAGEN, Denmark, July 6, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on June 2, 2026, under which the Company will repurchase shares for an amount up to [...]
Virbac : Declaration of the number of shares and voting rights 06/2026
06/07/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Virbac : Déclaration d'actions et de droits de vote 06/2026
06/07/2026
DÉCLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Astex Announces Exclusive Research Collaboration and License Agreement with Genentech for Breast Cancer Therapy Program
06/07/2026
Collaboration leverages Astex’s industry-leading, fragment-based drug discovery capability to target a key cell-cycle-dependent regulator in breast cancer Astex to receive an upfront and potential milestone payments, [...]
Myricx Bio to be Acquired by Novartis to Advance Next-Generation ADC Payloads for Oncology with Novel NMTi Platform
06/07/2026
Potential first-in-class N-myristoyltransferase inhibitor (NMTi) ADC payload with a differentiated mechanism of action Combines oncology expertise of Novartis with Myricx Bio’s novel ADC assets and platform having broad [...]
Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients
06/07/2026
Adds potential first-in-class, N-myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform, designed to address resistance to current payloads Strengthens the Novartis oncology pipeline with [...]
REPRONOVO ANNOUNCES FIRST PARTICIPANT DOSED IN EU PHASE 2 TRIAL OF RPN-002 FOR EMBRYO IMPLANTATION
06/07/2026
Lausanne, Switzerland and Copenhagen, Denmark, July 06, 2026 (GLOBE NEWSWIRE) -- REPRONOVO ANNOUNCES FIRST PARTICIPANT DOSED IN EU PHASE 2 TRIAL OF RPN-002 FOR EMBRYO IMPLANTATION RPN-002 is an orally administered [...]

Pages